Literature DB >> 25445104

Use of medical, surgical and complementary treatments among women with fibroids.

Vanessa L Jacoby1, Alison Jacoby2, Lee A Learman3, Michael Schembri2, Steven E Gregorich4, Rebecca Jackson5, Miriam Kuppermann6.   

Abstract

OBJECTIVE: To examine the use of medical management, uterus-preserving surgery (UPS), and complementary treatments among women with uterine fibroids. STUDY
DESIGN: Prospective cohort study of 933 premenopausal women ages 31-54 years with symptomatic fibroids who participated in the Study of Pelvic Problems, Hysterectomy, and Intervention Alternatives (SOPHIA) for an average of 4.3 years (SD 2.5 years). Incident use of fibroid treatments was determined through annual interviews. Linear regression models were used to compare changes in fibroid-related symptoms among women who underwent UPS versus those who did not undergo surgery.
RESULTS: Participants were racially and ethnically diverse, with a mean age of 43 years. During study follow-up, 531 participants (57%) did not undergo UPS or hysterectomy, 250 (27%) had at least one UPS, and 152 (16%) underwent hysterectomy. Complementary and alternative treatments were commonly used, including exercise (45%), diet (34%), herbs (37%), and acupuncture (16%): participants reported significant symptom improvement and few side effects with these interventions. In multivariable linear regression models, women who did not undergo surgery during the study reported improvement in dyspareunia (p<.001), pelvic pain (p<.001), and menstrual cramps (p<.001). However, women who underwent UPS reported greater overall resolution of "pelvic problems" compared with women who did not have surgical treatment (difference in change score 1.18 on a four-point Likert scale, p<.001).
CONCLUSION: UPS are effective treatments for women with fibroids, but many women use hormonal or complementary treatments and report significant symptom improvement without surgical intervention.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Complementary treatments; Myomectomy; Uterine artery embolization; Uterine fibroids

Mesh:

Substances:

Year:  2014        PMID: 25445104      PMCID: PMC4630000          DOI: 10.1016/j.ejogrb.2014.09.004

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  28 in total

Review 1.  Uterine myomas: an overview of development, clinical features, and management.

Authors:  Edward E Wallach; Nikos F Vlahos
Journal:  Obstet Gynecol       Date:  2004-08       Impact factor: 7.661

Review 2.  Role, epidemiology, and natural history of benign uterine mass lesions.

Authors:  Ginny L Ryan; Craig H Syrop; Bradley J Van Voorhis
Journal:  Clin Obstet Gynecol       Date:  2005-06       Impact factor: 2.190

3.  Use of oral contraceptives and uterine fibroids: results from a case-control study.

Authors:  F Chiaffarino; F Parazzini; C La Vecchia; S Marsico; M Surace; E Ricci
Journal:  Br J Obstet Gynaecol       Date:  1999-08

4.  Uterine myomas and factors associated with hysterectomy in premenopausal women.

Authors:  A M Weber; A R Mitchinson; G P Gidwani; E Mascha; M D Walters
Journal:  Am J Obstet Gynecol       Date:  1997-06       Impact factor: 8.661

5.  Predictors of leiomyoma recurrence after myomectomy.

Authors:  Magdi Hanafi
Journal:  Obstet Gynecol       Date:  2005-04       Impact factor: 7.661

6.  Obstetric outcomes in women with sonographically identified uterine leiomyomata.

Authors:  G Iram Qidwai; Aaron B Caughey; Alison F Jacoby
Journal:  Obstet Gynecol       Date:  2006-02       Impact factor: 7.661

7.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.

Authors:  D M Eisenberg; R B Davis; S L Ettner; S Appel; S Wilkey; M Van Rompay; R C Kessler
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

8.  Abdominal myomectomy: results of a simple operative technique.

Authors:  P Acién; F Quereda
Journal:  Fertil Steril       Date:  1996-01       Impact factor: 7.329

Review 9.  Benefits and risks of pharmacological agents used for the treatment of menorrhagia.

Authors:  Samendra Nath Roy; Siladitya Bhattacharya
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata.

Authors:  L M Marshall; D Spiegelman; M B Goldman; J E Manson; G A Colditz; R L Barbieri; M J Stampfer; D J Hunter
Journal:  Fertil Steril       Date:  1998-09       Impact factor: 7.329

View more
  6 in total

1.  Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata.

Authors:  Mark A Hayden; Zehra Ordulu; C Scott Gallagher; Bradley J Quade; Raymond M Anchan; Nia Robinson Middleton; Serene S Srouji; Elizabeth A Stewart; Cynthia C Morton
Journal:  Cancer Genet       Date:  2018-02-19

2.  A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years.

Authors:  D D Baird; T M Saldana; D L Shore; M C Hill; J M Schectman
Journal:  Hum Reprod       Date:  2015-09-25       Impact factor: 6.918

Review 3.  Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment.

Authors:  Folabomi A Oladosu; Frank F Tu; Kevin M Hellman
Journal:  Am J Obstet Gynecol       Date:  2017-09-06       Impact factor: 8.661

Review 4.  Symptomatic Fibroid Management: Systematic Review of the Literature.

Authors:  Yelena Havryliuk; Robert Setton; John J Carlow; Barry D Shaktman
Journal:  JSLS       Date:  2017 Jul-Sep       Impact factor: 2.172

5.  Comparison of conventional versus single port laparoscopy for surgical treatment of gynecological diseases: a pilot study.

Authors:  Ying Zhang; Yingjun Zhu
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-05-05       Impact factor: 1.195

Review 6.  Uterine Fibroids: Burden and Unmet Medical Need.

Authors:  Ayman Al-Hendy; Evan Robert Myers; Elizabeth Stewart
Journal:  Semin Reprod Med       Date:  2017-11-03       Impact factor: 1.303

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.